Summit Therapeutics (SMMT) Return on Capital Employed (2017 - 2024)
Historic Return on Capital Employed for Summit Therapeutics (SMMT) over the last 7 years, with Q4 2024 value amounting to 0.42%.
- Summit Therapeutics' Return on Capital Employed rose 700.0% to 0.42% in Q4 2024 from the same period last year, while for Dec 2024 it was 0.42%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.81% for FY2024, which is 6600.0% up from last year.
- Latest data reveals that Summit Therapeutics reported Return on Capital Employed of 0.42% as of Q4 2024, which was up 700.0% from 0.37% recorded in Q3 2024.
- In the past 5 years, Summit Therapeutics' Return on Capital Employed registered a high of 0.15% during Q4 2022, and its lowest value of 0.57% during Q3 2023.
- In the last 4 years, Summit Therapeutics' Return on Capital Employed had a median value of 0.38% in 2022 and averaged 0.38%.
- In the last 5 years, Summit Therapeutics' Return on Capital Employed tumbled by -3500bps in 2023 and then soared by 2000bps in 2024.
- Summit Therapeutics' Return on Capital Employed (Quarter) stood at 0.3% in 2020, then soared by 52bps to 0.15% in 2022, then plummeted by -237bps to 0.49% in 2023, then rose by 14bps to 0.42% in 2024.
- Its last three reported values are 0.42% in Q4 2024, 0.37% for Q3 2024, and 0.49% during Q4 2023.